Zealand Pharma A/S (ZLDPF)
USD 62.5
(0.0%)
USD 62.5
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 323.61 Million DKK | 341.64% |
| 2022 | 73.27 Million DKK | -57.83% |
| 2021 | 173.75 Million DKK | -33.87% |
| 2020 | 262.74 Million DKK | 542.14% |
| 2019 | 40.91 Million DKK | 128.76% |
| 2018 | -142.26 Million DKK | -213.68% |
| 2017 | 125.14 Million DKK | -38.45% |
| 2016 | 203.31 Million DKK | 22.92% |
| 2015 | 165.41 Million DKK | 18.15% |
| 2014 | 139.99 Million DKK | 2355.23% |
| 2013 | 5.7 Million DKK | -97.25% |
| 2012 | 207.63 Million DKK | 46.04% |
| 2011 | 142.17 Million DKK | 86.69% |
| 2010 | 76.15 Million DKK | 200.78% |
| 2009 | 25.31 Million DKK | -55.0% |
| 2008 | 56.26 Million DKK | -6.11% |
| 2007 | 59.92 Million DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 17.87 Million DKK | 536.09% |
| 2024 Q1 | 3.87 Million DKK | -58.0% |
| 2023 Q1 | -121.57 Million DKK | -620.7% |
| 2023 FY | 323.61 Million DKK | 341.64% |
| 2023 Q4 | 9.22 Million DKK | -96.82% |
| 2023 Q3 | 290.35 Million DKK | 5478.39% |
| 2023 Q2 | 5.2 Million DKK | 104.28% |
| 2022 Q4 | 23.34 Million DKK | -45.87% |
| 2022 FY | 73.27 Million DKK | -57.83% |
| 2022 Q3 | 43.13 Million DKK | 65.71% |
| 2022 Q2 | 26.03 Million DKK | 113.98% |
| 2022 Q1 | 12.16 Million DKK | -59.69% |
| 2021 Q4 | 30.17 Million DKK | -61.18% |
| 2021 Q2 | 41.76 Million DKK | 73.47% |
| 2021 FY | 173.75 Million DKK | -33.87% |
| 2021 Q1 | 24.07 Million DKK | -31.38% |
| 2021 Q3 | 77.73 Million DKK | 86.12% |
| 2020 Q3 | 22.25 Million DKK | -88.47% |
| 2020 Q2 | 192.99 Million DKK | 1454.24% |
| 2020 FY | 262.74 Million DKK | 542.14% |
| 2020 Q1 | 12.41 Million DKK | 8.04% |
| 2020 Q4 | 35.08 Million DKK | 57.66% |
| 2019 FY | 40.91 Million DKK | 128.76% |
| 2019 Q1 | - DKK | 100.0% |
| 2019 Q2 | 19.73 Million DKK | 0.0% |
| 2019 Q3 | 9.69 Million DKK | -50.89% |
| 2019 Q4 | 11.49 Million DKK | 18.59% |
| 2018 Q4 | -163.76 Million DKK | 0.0% |
| 2018 Q2 | 13.09 Million DKK | 39.78% |
| 2018 Q1 | 9.36 Million DKK | -3.96% |
| 2018 FY | -142.26 Million DKK | -213.68% |
| 2018 Q3 | - DKK | -100.0% |
| 2017 Q2 | 9.56 Million DKK | -85.75% |
| 2017 FY | 125.14 Million DKK | -38.45% |
| 2017 Q4 | 9.75 Million DKK | -74.79% |
| 2017 Q3 | 38.68 Million DKK | 304.26% |
| 2017 Q1 | 67.14 Million DKK | -57.0% |
| 2016 Q1 | 5.63 Million DKK | -96.18% |
| 2016 Q4 | 156.13 Million DKK | 355.76% |
| 2016 Q3 | 34.25 Million DKK | 383.2% |
| 2016 Q2 | 7.09 Million DKK | 25.82% |
| 2016 FY | 203.31 Million DKK | 22.92% |
| 2015 Q2 | 6.14 Million DKK | 11.96% |
| 2015 Q4 | 147.56 Million DKK | 2273.21% |
| 2015 FY | 165.41 Million DKK | 18.15% |
| 2015 Q1 | 5.48 Million DKK | 1.74% |
| 2015 Q3 | 6.21 Million DKK | 1.25% |
| 2014 Q3 | 57.37 Million DKK | 1445.11% |
| 2014 Q4 | 5.39 Million DKK | -90.6% |
| 2014 FY | 139.99 Million DKK | 2355.23% |
| 2014 Q1 | 73.52 Million DKK | 2564.84% |
| 2014 Q2 | 3.71 Million DKK | -94.95% |
| 2013 FY | 5.7 Million DKK | -97.25% |
| 2013 Q4 | 2.75 Million DKK | 37.33% |
| 2013 Q3 | 2 Million DKK | 115.1% |
| 2013 Q2 | 934 Thousand DKK | 0.0% |
| 2013 Q1 | - DKK | 100.0% |
| 2012 Q2 | 65.62 Million DKK | -37.51% |
| 2012 Q1 | 105.01 Million DKK | 370.57% |
| 2012 FY | 207.63 Million DKK | 46.04% |
| 2012 Q4 | -372 Thousand DKK | -101.0% |
| 2012 Q3 | 37.36 Million DKK | -43.06% |
| 2011 Q2 | 119.29 Million DKK | 0.0% |
| 2011 Q4 | 22.31 Million DKK | 3230.75% |
| 2011 Q1 | - DKK | -100.0% |
| 2011 FY | 142.17 Million DKK | 86.69% |
| 2011 Q3 | 670 Thousand DKK | -99.44% |
| 2010 Q1 | - DKK | 0.0% |
| 2010 FY | 76.15 Million DKK | 200.78% |
| 2010 Q2 | 82.84 Million DKK | 0.0% |
| 2010 Q3 | 782 Thousand DKK | -99.06% |
| 2010 Q4 | 3.72 Million DKK | 376.6% |
| 2009 FY | 25.31 Million DKK | -55.0% |
| 2008 FY | 56.26 Million DKK | -6.11% |
| 2007 FY | 59.92 Million DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | -3267.121% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 260551.827% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -171.699% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 101385.418% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 670677.509% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 13268406.683% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1998.005% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -183188.401% |
| CSL Limited | 7.56 Billion USD | 95.72% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 1354.415% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -2664.514% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -230230.249% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -2057.571% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -10432330.69% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -3204.207% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -492253.335% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 947725.183% |
| Mesoblast Limited | -35.16 Million USD | 1020.194% |
| Marizyme, Inc. | 457.7 Thousand USD | -70604.083% |
| Genus plc | 178.7 Million USD | -81.093% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -47.028% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -519962.353% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -78798.492% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 2942045.455% |
| ContraFect Corporation | -154 Thousand USD | 210238.961% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 647328.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -421486.483% |
| IMV Inc. | -962.29 Thousand USD | 33729.292% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 83613.075% |
| MultiCell Technologies, Inc. | 49.32 USD | -656151562.612% |
| ONE Bio Corp. | 20.12 Million USD | -1507.985% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -703.71% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -661687.321% |
| Q BioMed Inc. | -8988.00 USD | 3600611.794% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -1045.334% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 2098219.813% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -629.554% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 28448.102% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -462205.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 6535116.155% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 331960.739% |
| GB Sciences, Inc. | -624.00 USD | 51861317.949% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 376272.874% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 155583753.846% |
| Enzolytics Inc. | 30.7 Thousand USD | -1053742.647% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -66979.574% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 70.806% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 62997.514% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -52316.972% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 20.984% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 3654277.958% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 386048.55% |
| Kadimastem Ltd | -630.13 Thousand USD | 51456.052% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -32655.083% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 2734481.073% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -183188.401% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -23745.24% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1116010.345% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -71807.351% |
| SYBLEU INC | 11.69 Thousand USD | -2766777.565% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -6922.873% |
| Bioxytran, Inc. | -8285.00 USD | 3906122.933% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 86859.786% |
| Neutra Corp. | 14.33 Thousand USD | -2257409.592% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 394751.22% |
| PureTech Health plc | -1.6 Million USD | 20288.022% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 32421.451% |
| IXICO plc | 3.27 Million USD | -9796.453% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 46730.259% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 18168.9% |
| CSL Limited | 7.7 Billion USD | 95.8% |
| Cellectis S.A. | 18 Thousand USD | -1797755.556% |